Irinotekan Viatris (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, preventing the religation of single‑strand DNA breaks during replication. This leads to accumulation of DNA damage, replication arrest and ultimately triggers apoptosis of rapidly dividing cancer cells.

The dose of Irinotekan is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, prior therapies and laboratory values. The prescriber determines the appropriate infusion schedule and any dose adjustments needed for safety.

Safety data for Irinotekan during pregnancy and lactation are limited. Because the drug can cross the placenta and may be excreted in breast milk, it is generally avoided unless the potential benefit to the mother outweighs the potential risk to the fetus or infant. Consultation with a specialist is essential.

To order Irinotekan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

The primary alternative to irinotecan in colorectal cancer regimens is topotecan, another topoisomerase I inhibitor, though it is less commonly used for this indication. Irinotecan generally offers a broader evidence base for metastatic colorectal cancer and is often combined with fluoropyrimidines and oxaliplatin, providing a more established efficacy profile compared with newer agents.

Irinotekan must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken. Before preparation, keep the vial in its original packaging and handle with aseptic technique to maintain sterility.

Irinotekan is administered by intravenous infusion. The drug is diluted in an appropriate compatible IV fluid and infused over a period that may range from 30 minutes to several hours, depending on the prescribed regimen and patient tolerance. Administration is performed under medical supervision in an oncology setting.

The most serious risks include severe neutropenia that can lead to life‑threatening infections, febrile neutropenia, and severe diarrhea that may cause dehydration and electrolyte imbalance. Acute cholinergic syndrome, characterized by abdominal cramping, sweating and bradycardia, is also a rare but critical adverse event requiring immediate medical attention.

Irinotekan should not be used in patients with known hypersensitivity to irinotecan or any of its excipients. It is also contraindicated in individuals with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment that would impair SN‑38 metabolism. Caution is advised for pregnant or breastfeeding women.